Author:
Taylor Joseph J.,Kurt Hatice Guncu,Anand Amit
Abstract
There are currently no validated treatment biomarkers in psychiatry. Resting State Functional Connectivity (RSFC) is a popular method for investigating the neural correlates of mood disorders, but the breadth of the field makes it difficult to assess progress toward treatment response biomarkers. In this review, we followed general PRISMA guidelines to evaluate the evidence base for mood disorder treatment biomarkers across diagnoses, brain network models, and treatment modalities. We hypothesized that no treatment biomarker would be validated across these domains or with independent datasets. Results are organized, interpreted, and discussed in the context of four popular analytic techniques: (1) reference region (seed-based) analysis, (2) independent component analysis, (3) graph theory analysis, and (4) other methods. Cortico-limbic connectivity is implicated across studies, but there is no single biomarker that spans analyses or that has been replicated in multiple independent datasets. We discuss RSFC limitations and future directions in biomarker development.
Subject
Psychiatry and Mental health
Reference184 articles.
1. DSM-5 field trials in the United States and Canada, Part I: study design, sampling strategy, implementation, and analytic approaches;Clarke;Am J Psychiatry.,2013
2. DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses;Regier;Am J Psychiatry.,2013
3. DSM-5 field trials in the United States and Canada, Part III: development and reliability testing of a cross-cutting symptom assessment for DSM-5;Narrow;Am J Psychiatry.,2013
4. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry;Insel;Am J Psychiatry.,2014
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献